Search Results - Potestio L

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study by Megna M, Potestio L, Fabbrocini G, Ruggiero A

Connect to this object online.

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis by Potestio L, Martora F, Fabbrocini G, Battista T, Megna M

Connect to this object online.

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments by Battista T, Scalvenzi M, Martora F, Potestio L, Megna M

Connect to this object online.

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature by Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M

Connect to this object online.

Herpes Zoster and COVID-19 Vaccination: A Narrative Review by Potestio L, Megna M, Villani A, Cacciapuoti S, Scalvenzi M, Martora F

Connect to this object online.

Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report by Martora F, Battista T, Potestio L, Portarapillo A, Tommasino N, Megna M

Connect to this object online.

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials by Potestio L, Martora F, Lauletta G, Vallone Y, Battista T, Megna M

Connect to this object online.

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study by Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M

Connect to this object online.

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge by Ruggiero A, Potestio L, Camela snr E, Fabbrocini G, Megna M

Connect to this object online.

L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter] by Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A

Connect to this object online.

Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report by Martora F, Annunziata MC, Potestio L, Battista T, Ruggiero A, Megna M

Connect to this object online.

Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review by Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A

Connect to this object online.

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature by Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L

Connect to this object online.

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection by Potestio L, Piscitelli I, Fabbrocini G, Martora F, Ruggiero A, Megna M

Connect to this object online.

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? by Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, Potestio L

Connect to this object online.

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study by Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, Potestio L

Connect to this object online.

Towards Personalized Medicine in Psoriasis: Current Progress by Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M

Connect to this object online.

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data by Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M

Connect to this object online.

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review by Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F, Battista T, Megna M

Connect to this object online.

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study by Martora F, Marasca C, Cacciapuoti S, Fariello F, Potestio L, Battista T, Scalvenzi M, Megna M

Connect to this object online.